Department of Dermatology, University Hospital, Erlangen, Germany.
Division of Nephrology and Hypertension, Diabetes and Metabolism Lab, Azrieli Faculty of Medicine in Galilee, Baruch Padeh Poriya Medical Center, Lower galilee 15208, Ramat-Gan, Israel.
Int Urol Nephrol. 2020 Sep;52(9):1705-1712. doi: 10.1007/s11255-020-02545-4. Epub 2020 Jul 13.
Diabetes mellitus (DM) is the leading cause of end stage renal disease. 40% of the patients worldwide will require replacement therapy after 20 years of DM worldwide. Early-stage diabetic nephropathy is characterized by hyperfiltration related to hypeglycemia-induced afferent artery vasodilatation with micro-and macroalbuminuria. Later on, proteinuria with arterial hypertension may appear, culminating in glomerular filtration rate (GFR) decline and end stage renal disease. Forty percent of diabetic patients develop microvascular and macrovascular complications, with increased risk among patients with genetic predisposition, such as Haptoglobin 2-2 phenotype. The most frequent complications in the daily clinical practice are diabetic kidney disease, diabetic retinopathy and vascular disease, such as coronary artery disease and stroke. Various pathways are involved in the pathogenesis of diabetic kidney disease. Chronic systemic inflammation and the inflammatory response, such as increased circulating cytokines (Interleukins), have been recognized as main players in the development and progression of diabetic kidney disease. DM is also associated with increased oxidative stress, and alterations in carbohydrate, lipid and protein metabolism. Overexpression of the renin-angiotensin-aldosterone system (RAAS) in the kidney, the vitamin D-Vitamin D receptor-klotho axis, and autophagy. Differences in the ATG5 protein levels or ATG5 gene expression involved in the autophagy process have been associated with diabetic complications such as diabetic kidney disease. Under normal blood glucose level, autophagy is an important protective mechanism in renal epithelial cells, including podocytes, proximal tubular, mesangial and endothelial cells. Down regulation of the autophagic mechanism, as in hyperglycemic condition, can contribute to the development and progression of diabetic kidney disease.
糖尿病(DM)是终末期肾病的主要原因。全世界 40%的患者在 DM 后 20 年内将需要替代治疗。早期糖尿病肾病的特征是高滤过,与高血糖诱导的入球小动脉扩张有关,伴有微量和大量白蛋白尿。之后,可能会出现蛋白尿伴动脉高血压,最终导致肾小球滤过率(GFR)下降和终末期肾病。40%的糖尿病患者会出现微血管和大血管并发症,具有遗传易感性的患者(如 Haptoglobin 2-2 表型)风险增加。在日常临床实践中最常见的并发症是糖尿病肾病、糖尿病视网膜病变和血管疾病,如冠状动脉疾病和中风。糖尿病肾病的发病机制涉及多种途径。慢性全身炎症和炎症反应,如循环细胞因子(白细胞介素)增加,已被认为是糖尿病肾病发展和进展的主要参与者。DM 还与氧化应激增加以及碳水化合物、脂质和蛋白质代谢改变有关。肾素-血管紧张素-醛固酮系统(RAAS)、维生素 D-维生素 D 受体-klotho 轴和自噬的过度表达。自噬过程中涉及的 ATG5 蛋白水平或 ATG5 基因表达的差异与糖尿病并发症如糖尿病肾病有关。在正常血糖水平下,自噬是包括足细胞、近端肾小管、系膜和内皮细胞在内的肾上皮细胞的重要保护机制。自噬机制下调,如高血糖状态,可导致糖尿病肾病的发生和进展。